BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
GMP Human TNF-alpha Protein (Cat. No. GMP-TNAH23) is expressed in human 293 cells (HEK293) and comprises amino acids Val 77 to Leu 233 (Accession # P01375). This protein has no "tag". It has a ...
Potential entry into high growth GLP-1 market of nearly $50 billion in 2024, projected value of $100 billion by 2029 BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the ...
Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...
TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for ...
Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the “Company”), a ...
Genetic markers, specifically tumor necrosis factor alpha receptor 2 (TNFR2) gene polymorphisms, may predict response to TNF inhibitor therapy in patients with rheumatoid arthritis (RA). This approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results